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Abstract 
Objective The aim of this project was to assess 
pharmacist intervention in patients suffering from 
hypertension to improve management of their condition by 
identifying risk factors, evaluating side-effects, monitoring, 
assessing drug-drug interactions and providing advice to 
help control blood pressure. 
Method Two questionnaires were used in the study; the 
first questionnaire intended to identify drug-related problems 
and risk factors and a second questionnaire was developed as 
a shorter version of the first questionnaire.  The questionnaires 
were used on 3 occasions when the patients came to collect 
their Pharmacy of Your Choice (POYC) medications from a local 
community pharmacy. The first questionnaire was used at 
time=0 (visit 1) and the second questionnaire was used twice, 
at t=2 months (visit 2) and t=4 months (visit 3).  Blood pressure 
and pulse readings were recorded each time and patients 
were referred in cases of abnormal readings and in cases of 
interactions or side-effects. Advice was given to the patients 
on all the 3 occasions and any care issues were addressed.
Key findings Out of the 35 patients who 
participated, initially 22 patients were hypertensive. This 
number decreased to 20 patients at t=2 months and 16 
patients at  t=4 months. Abnormal pulse readings were 
initially found in 7 patients that in the subsequent visits 
decreased to 4 patients with 2 patients being investigated. 
The need for patient referral decreased from 24 patients at 
t= 0, to 21 patients at t= 2 months and 17 at t= 4 months.
Conclusion Pharmacist intervention in patient 
monitoring of chronic conditions supported patients in 
managing their blood pressure. Several comorbidities and 
mortalities can be reduced when the patient is regularly 
monitored by a pharmacist and any drug-related problems 
identified, addressed and patient is referred as necessary.
Keywords Community pharmacist intervention, 
hypertension, POYC, patient monitoring, care issues.
Introduction
Hypertension remains one of the major and most common 
health conditions in the world leaving a large and direct 
impact on the patient and on each country’s health system. 
Hypertension accounts for “more than 5.8% of total deaths, 
1.9% of years of life lost and 1.4% disability adjusted life 
years all over the world and less than 20% of patients 
have their blood pressure under control”.1 It is estimated 
that there are more than 1 billion people suffering from 
hypertension worldwide.2 
Recently, new target blood pressure readings have been 
introduced causing an increase in the reported number of 
untreated patients or mismanaged patients.3 It is estimated 
that the number of patients with poor blood pressure 
control has increased to 72%.4 This strongly emphasises 
the importance of the intervention of the pharmacist who, 
through for example the Pharmacy of Your Choice (POYC) 
scheme, will be in a better position to support patients in 
chronic disease management. The pharmacist in primary 
care is in an ideal position to ensure that the patient is well 
managed and correctly taking medications as prescribed. 
Pharmacists can regularly monitor patients’ blood pressure 
when they visit the community pharmacy or clinic, helping 
them to improve management of their blood pressure 
and identify any drug-related problems. Patients who are 
not being appropriately managed can be referred and 
any mismanagement issues and errors, including dosing 
errors and irrationalised treatment can be identified and 
addressed immediately.  
In these scenarios, patients are monitored regularly 
through the continuous direct intervention of pharmacists 
who are the most accessible healthcare professionals in the 
community.  
The aim of this study was to assess pharmacist intervention 
in patients suffering from hypertension to improve 
management of their condition by identifying risk factors, 
evaluating side-effects, monitoring, assessing drug-drug 
interactions and providing advice to help control blood 
pressure. 
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Method
Approval from the University of Malta Research Ethics 
Committee, POYC management and from the owner of the 
community pharmacy selected for the study was sought. 
Patients who came to collect their POYC medication 
from the pharmacy were approached and asked whether 
they were willing to participate. Patients were given a 
letter prior to study initiation where the aims of the study 
were explained and those accepting to participate were 
requested to sign a consent form.
Thirty five patients participated in the study by completing 
the first questionnaire. In this questionnaire completed at 
time 0, risk factors for hypertension were identified, Body 
Mass Index (BMI) was calculated, blood pressure and pulse 
readings were taken twice and an average was calculated 
and recorded, treatment was noted and side-effects were 
identified. Any drug interactions were also noted after a 
thorough drug history was taken for each patient. Blood 
pressure was taken after the patient had been at rest for at 
least ten minutes and the arm with the highest reading was 
used at throughout.
Patients repeated the second questionnaire 2 and 4 months 
later when their POYC medication was due to be collected 
again. This questionnaire was a shorter version of the 
first one and was used to obtain BMI, blood pressure and 
pulse readings and any changes in the pharmacological 
treatment since the previous meeting. Any problems and 
drug interactions were noted once again. Blood pressure, 
pulse readings and BMI were documented on a patient 
card to maintain a record and for easy follow-up by another 
healthcare professional in the future. 
Patients who had abnormal blood pressure readings or 
pulse readings or who experienced severe side-effects 
were referred to their physician. Verbal advice was also 
given to patients especially during the first meeting where 
risk factors were being assessed and when directions about 
treatment were required. The data was evaluated after all 
the patients completed the questionnaires during the 3 
visits.
Results
Thirty five patients participated in the study out of which 
16 were male and 19 were female. The average age of the 
patients was 60.5 years (range 45 to 76 years).  
Patients’ BMI showed that most patients were obese (n=25), 
8 patients were overweight and only 2 patients had a 
normal weight. Patients’ weight range was recorded as 55 
to 140kg at time 0 and 52 to 140 kg at time 4 months.  
When risk factors were assessed, it was found that obesity 
was the highest risk factor with 33 patients, followed by a 
family history of cardiovascular disease in 25 patients and 
high blood cholesterol levels in 24 patients. Smoking was 
found to be a risk factor in only 3 patients while alcohol 
intake was a risk factor in 2 patients. Seventeen patients 
reported that they were not exercising, not even for half an 
hour once a week. Thirteen patients admitted to have a diet 
with a high salt intake (Figure 1). 
Figure 1: Risk factors identified amongst patients (n=35)
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The most common treatment option (28 patients) was 
an angiotensin-converting enzyme (ACE) inhibitor or 
angiotensin-II receptor antagonist (ARB) with most 
patients also taking another drug in (20 patients). The most 
common combination was with diuretics (7 patients). As a 
result of the pharmacist interventions and the subsequent 
referrals there were 8 patients who had their treatment 
plan modified. In 4 patients, an increase in dose between 
t=0 and t=2 months was implemented, 3 patients had an 
increase in dose between the t=2 and t=4 months and 1 
patient had a treatment modification from an ACE inhibitor 
to an ARB due to development of side-effects between t=2 
and t=4 months.
Side effects reported by patients included daytime fatigue 
(17 patients), followed by dry mouth (15 patients) and 
faintness and dizziness (14 patients) (Figure 2).
Despite receiving treatment, 22 patients presented with 
high blood pressure values during the first visit, 20 patients 
during the second visit and 16 patients during the third 
visit. Seven patients also had abnormal pulse readings on 
the first visit while 4 patients had abnormal pulse readings 
on the second and third visit. Two of these patients were 
being investigated because of their high pulse readings. 
Following patient monitoring, the need for patient referral 
decreased throughout the 3 visits; from 24 patients at t=0, 
to 21 at t=2 and 17 at t=4 months.
Figure 2: Side effects reported by patients (n=35)
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Despite receiving treatment, 22 patients presented 
with high blood pressure values during the first 
visit, 20 patients during the second visit and 16 
patients during the third visit.  
Discussion
Similar to published studies, results show that pharmacist 
intervention helped patients in the normalisation of blood 
pressure and pulse results.5 This study demonstrates 
how pharmacist intervention and extended professional 
services could be included in the POYC scheme to impact 
on rationale management of hypertension.  The pharmacist 
helped in monitoring patients over a period of four months, 
ensuring that the patients are taking their medication 
correctly as prescribed and referring patients in cases of 
irrational treatment, in cases where the condition is not 
being successfully managed and in cases where other 
drug-related problems were identified. Despite the fact 
that patients had been on long-term treatment, a number 
of them were still uncontrolled whilst the majority were 
not having their blood pressure regularly monitored. This 
reflects the need for frequent pharmacist interventions 
when patients are collecting their POYC medication every 
two months. Using such a scheme ensures that there is a 
constant, regular contact with patients, on-site monitoring, 
immediate referral when required and increased 
compliance.  
There are numerous benefits of involving a pharmacist in 
the management of hypertension including reduction in 
co-morbidities and mortality and avoidance of 
complications, requiring prolonged hospital admissions and 
additional treatment. Thus, it would be more cost-effective 
to involve pharmacists in the management of patients 
with hypertension to decrease or avoid emergencies and 
hospitalisations. Locally, the pharmacist is very accessible 
and patients can easily consult their pharmacist to monitor 
their blood pressure. In so doing, they would avoid having 
to be referred to a physician or having to wait long hours 
at the health centre to check their blood pressure. The 
pharmacist can spend more time with the patient in cases 
of problems and queries leading to better communication 
and ultimately improved compliance. Patients with 
chronic conditions have more contact with the community 
pharmacists than any other healthcare professional.6
Limitations of the study were the time framework since 
monitoring could be extended over a longer period of time 
and a small sample size since the number of   patients willing 
to complete the study over the four months was limited.  
Conclusion
Hypertension management by pharmacists improves 
outcomes in blood pressure control and in communication 
with the patient. Considering all the recent updates 
in guidelines, the number of patients suffering from 
hypertension may rise, thus, increasing the need for 
awareness and for more pharmacist-led patient monitoring. 
This will provide a cost-effective scenario since by rigorous 
monitoring, hospital admissions, morbidity and mortality 
are reduced, thus decreasing both direct and indirect costs. 
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